Scientists have faced obstacle after obstacle in the search for effective Alzheimer’s drugs. While there are a number of symptomatic drugs approved by the…
Vaccines are considered one of the greatest innovations in medical history. Immunizations help train the body’s immune system to recognize and respond to a…
UPDATE: 3 March 2024, 8:30 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
UPDATE: 3 March 2024, 8:37 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The FDA approves a new, transdermal form of donepezil called Adlarity, a skin patch for treating Alzheimer’s symptoms. Experts say it could be easier…
In February of this year, the Centers for Medicare and Medicaid Services (CMS) released a confusing proposal to dramatically limit insurance coverage for Aduhelm,…
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
The lack of effective treatments for Alzheimer’s have spurred scientists to rethink the dominant approach to tackling the disease: the amyloid hypothesis. This hypothesis…
UPDATE: 3 March 2024, 8:27 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Here’s how VOA’s 5 founders — including reporter Phil Gutis — responded to recent Aduhelm Medicare announcement. A few months ago, I received an…
UPDATE: 3 March 2024, 8:18 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
What’s the difference between treating Alzheimer’s symptoms and modifying the disease? Despite decades of research, the underlying cause of Alzheimer’s continues to evade scientists….
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Analysts had high hopes for anti-amyloid drug Aduhelm — the first Alzheimer’s treatment approved by the FDA in nearly two decades and the first…